Improving outcomes in pancreatic cancer: Key points in perioperative management

Table 2 Results of the three published meta-analyses on neo-adjuvant therapy in pancreatic carcinoma in terms of safety (postoperative morbidity and toxicity) and efficacy (response and resection)

		Response (%)			Resection (%)
	Toxicity (%)	Complete	Partial	Progression	Resected	R0	Mono	Combined	Postoperative morbidity (%)
Gillen et al[2]	01:26.3	3.6	30.6	20.9	73.6	60.4	80.9	66.2	26.7
	02:31.3	4.8	30.2	20.8	33.2	26.2	27.3	33.0	39.1
Assifi et al[35]	1:37	0.8	9.5	17.0	65.8	55.9	N/P	N/P	N/P
	02:46.2	4.0	31.8	21.8	31.6	19.6			N/P
Andriulli et al[36]	1:29	12		15.0	81.2	66.4	N/P	N/P	N/P
	2:33	27		32.0	26.4	16.0			N/P

1: Group of patients with potentially resectable pancreatic adenocarcinoma; 2: Group of patients with borderline resectable pancreatic adenocarcinoma. Toxicity: Only grade 3 and 4; Resection R0: Complete resection of the tumor; Resection Mono: Single chemotherapy drug; Resection Combined: Combined chemotherapy drugs; N/P: Not provided.